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Background: Infants with severe bronchopulmonary dysplasia (BPD) are commonly treated
with off-label drugs due to lack of approved therapies. To prioritize drugs for rigorous efﬁcacy
and safety testing, it is important to describe exposure patterns in this population.
Objective: Our objective was to compare rates of drug exposure between preterm infants
with severe bronchopulmonary dysplasia based on respiratory support status at or beyond
36 weeks post-menstrual age.
Methods: A cross-sectional cohort study was performed on October 29, 2019. Preterm
infants with severe BPD were eligible and details of respiratory support and drug therapy
were recorded. Wilcoxon paired signed rank test was used to compare continuous
variables between the invasive and non-invasive groups. Fisher’s exact test was used
to compare binary variables by respiratory support status.
Results: 187 infants were eligible for the study at 16 sites. Diuretics were the drug class
that most subjects were receiving on the day of study comprising 54% of the entire cohort,
followed by inhaled steroids (47%) and short-acting bronchodilators (42%). Infants who
were invasively ventilated (verses on non-invasive support) were signiﬁcantly more likely to
be receiving diuretics (p 0.013), short-acting bronchodilators (p < 0.01), long-acting
bronchodilators (p < 0.01), systemic steroids (p < 0.01), systemic pulmonary
hypertension drugs (p < 0.01), and inhaled nitric oxide (p < 0.01).
Conclusion: Infant with severe BPD, especially those who remain on invasive ventilation at
36 weeks, are routinely exposed to multiple drug classes despite insufﬁcient
pharmacokinetic, safety, and efﬁcacy evaluations. This study helps prioritize subpopulations, drugs and drug classes for future study.
Keywords: neonate, bronchopulmonary dysplasia, epidemiology - descriptive, diuretic, inhaled steroid,
bronchodilator
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INTRODUCTION

28 days of O2 after birth and were currently on invasive
mechanical ventilation or non-invasive support with ≥ 30% O2
or nasal CPAP or high ﬂow nasal canula (HFNC) >2 L per
minute. Infants were excluded if they were deemed by local
study staff to be on non-invasive support or mechanical
ventilation
for
surgical,
neurologic,
or
anatomic
(i.e., congenital lung malformations, airway anomalies, etc.)
reasons. These infants were excluded because BPD was not the
reason they were receiving respiratory support. For data analysis,
the cohort was divided into two binary groups, invasive
mechanical ventilation (via a tracheostomy or endotracheal
tube) versus non-invasive respiratory support (everyone else).
The study created a comprehensive list of drugs used in the
treatment
of
sBPD
(furosemide,
bumetanide,
hydrochlorothiazide, spironolactone, albuterol, levalbuterol,
atrovent, formoterol, ﬂuticasone, budesonide, beclamethasone,
hydrocortisone, dexamethasone, prednisone, prednisolone,
methylprednisolone, ranitidine, pantoprazole, omeprazole,
sildenaﬁl, bosentan, inhaled nitric oxide, Treprostinil, iloprost,
epoprostenol). Using this list, the study team at each site recorded
drug exposure on the study day for eligible infants. To accomplish
data abstraction, local study members opened the central RedCap
database and examined each infant’s local electronic medical
record. Data from the electronic medical record was transferred
to the research RedCap database. Only standing medication
orders (not PRN or one-time orders) were included in the
dataset. Data was abstracted from the chart at 8 am local time
on the day of the study.
Based on rates of drug exposure in infants with severe BPD
(Bamat et al., 2019), we estimated that 80% of intubated infants
and 50% of non-intubated infants would be on the most used
BPD drug class, diuretics. Using this predicted different in
exposure, enrolling 87 infants gives an 80% power to detect a
difference in groups using a p-value of 0.05 with two-tailed
testing. Wilcoxon paired signed rank test was used to compare
continuous variables between the invasive and non-invasive
groups. Fisher’s exact test was used to compare binary
variables by respiratory support status (invasive versus noninvasive).

Bronchopulmonary dysplasia (BPD) is a chronic lung disease
resulting from prematurity and is made worse by mechanical
ventilation as well as infectious and inﬂammatory insults to the
developing lungs in the post-natal period. While the pathogenesis
of BPD is complex and multi-factorial, there are salient clinical
features in established BPD that prompt trials of drug therapy in
the inpatient and outpatient setting (Thebaud et al., 2019). These
drug classes include corticosteroids to reduce airway and
parenchymal inﬂammation, beta-agonists to dilate constricted
airways, diuretics to treat pulmonary edema, and vasodilators to
treat pulmonary hypertension. None of the currently used drugs
for BPD are FDA approved in this population and few have
undergone rigorous efﬁcacy and safety studies in this population
(Abman et al., 2017).
There are many efforts underway aimed at improved neonatal
and infant therapeutics (Mulugeta et al., 2017). National
legislation, new multi-stakeholder collaboratives (International
Neonatal Consortium) and pediatric clinical trial networks (PTN,
i-ACT) are all working to advance drug approvals. One major
issue speciﬁc to infants with BPD is extensive off-label drug use
and no clear prioritization of which drugs and drug classes should
be studied and approved ﬁrst (Sheehan et al., 2020).
Pharmacoepidemiology studies can assess rates of real-world
drug exposure in speciﬁc patient populations, allowing
scientists and regulators to better understand which drugs are
used most and may therefore be optimal targets for improved
study and labelling.
The goal of this study was to describe the modern-day point
prevalence of drug exposure in a cohort of infants with severe
BPD (sBPD), as deﬁned by the 2001 consensus recommendation
from the National Institutes of Health workshop: receipt of
supplemental oxygen for >28 days in infants born <32 weeks
gestation with a need for ≥ 30% fraction of inspired oxygen
(FiO2) and/or positive pressure respiratory support (nasal
continuous positive airway pressure CPAP (CPAP), or invasive
mechanical ventilation) at 36 weeks post-menstrual age (PMA)
(Jobe and Bancalari, 2001). In addition, we are interested in
understanding variability in drug exposures by respiratory
support status.

RESULTS
METHODS

A total of 16 sites from 15 centers across the United States
submitted data. The number of infants from each site that met
inclusion criteria on the study day ranged from 3 to 28 infants. A
total of 187 of the 192 infants had sufﬁciently complete
ventilation and drug information data for data analysis.
Infants who remained on invasive mechanical ventilation at
36 weeks PMA had a median birth weight of 636 g (IQR 540,889),
median gestational age at birth of 25 weeks (IQR 24,27) and
median PMA of 52 weeks (IQR 44,64) on the study day. Infant
who were on non-invasive respiratory support on the study day
had a median birth weight of 750 g (IQR 625,950; p  0.009
compared to invasive mechanical ventilation), median gestational
age at birth of 25 weeks (IQR 24,27; p  0.91) and median PMA of
43 weeks (IQR 40,47; p < 0.0001) on the study day (Table 1).

The BPD Collaborative designed and executed a multi-site point
prevalence study on mechanical ventilation use in this
population. In addition, for this study, all centers provided
data on drugs that the de-identiﬁed study subjects were
receiving. All participating sites received institutional review
board approval prior to data submission.
This is a cross-sectional cohort study performed on a single
day across multiple academic centers which are all part of the
BPD Collaborative. The study took place on October 29, 2019. On
that day, eligible infants were less than 24 months of age, were
<32 weeks gestational age (GA) at birth and had a PMA ≥
36 weeks on the study day. Eligible infants received at least
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TABLE 1 | Entire cohort and ventilation group demographics.

Gestational age at birth (binned by week)b
Birthweight (grams)b
Male, N
Female, N
PMA on study day (binned by week)b
Weight on study day (grams)b

Entire cohort (N = 187)

Invasive ventilation (N = 94)

Non-invasive ventilation (N = 93)

p-valuea

25 (24,27)
710 (560,940)
112
75
46 (41,57)
4,437 (3100,6085)

25 (24,27)
636 (540,889)
55
39
52 (44,64)
5,435 (3780,7606)

25 (24,27)
750 (625,950)
57
36
43 (40,47)
3,690 (2838,4775)

0.91
0.009
0.77
<0.0001
<0.0001

a

Invasive versus non-invasive ventilation groups.
Median (IQR).
PMA is post-menstrual age.
b

ventilation group and 13% in the non-invasive respiratory support
group (p  <0.01).
Infants who were invasively ventilated (verses non-invasively)
were signiﬁcantly more likely to be receiving diuretics (p 0.013),
short-acting bronchodilators (p < 0.01), long-acting bronchodilators
(p < 0.01), systemic steroids (p < 0.01), systemic pulmonary
hypertension drugs (p < 0.01) and inhaled nitric oxide (p < 0.01).
There was no signiﬁcant difference in exposure to inhaled steroids
or anti-acid drugs by ventilation status (Table 2).

TABLE 2 | Point Prevalence of drug exposures by ventilation group.
Invasive
ventilation
(N = 94)
Drug Class
Diuretics
Furosemide
Bumetanide
Hydrochlorothiazide
Spironolactone
Short-acting
bronchodilator
Albuterol
Levalbuterol
Long-acting
bronchodilators
Atrovent
Formoterol
Inhaled steroidsa
Fluticasone
Budesonide
Systemic steroids
Hydrocortisone
Dexamethasone
Prednisolone
Methylprednisolone
Anti-acid drugs
Ranitidine
Pantoprazole
Omeprazole
Systemic pulm
hypertension
Sildenaﬁl
Bosentan
Inhaled nitric oxide

60
36
1
38
5
55

(64)
(38)
(1)
(40)
(5)
(59)

Non-invasive
ventilation
(N = 93)

42
19
1
30
10
24

p-value

(45)
(20)
(1)
(32)
(11)
(26)

0.013
0.01
1.00
0.29
0.19
<0.01

54 (57)
2 (2)
21 (22)

21 (23)
3 (3)
7 (8)

<0.01
0.68
0.007

21 (22)
0 (0)
49 (52)
26 (28)
24 (26)
40 (43)
20 (21)
7 (7)
17 (18)
2 (2)
18 (19)
9 (10)
1 (1)
8 (9)
26 (28)

4
3
38
20
18
17
8
4
7
0
8
5
0
3
7

<0.01
0.12
0.14
0.40
0.38
<0.01
0.02
0.54
0.05
0.50
0.056
0.41
1.00
0.21
<0.01

26 (28)
3 (3)
10 (11)

(4)
(3)
(41)
(22)
(19)
(18)
(9)
(4)
(8)
(0)
(9)
(5)
(0)
(3)
(8)

6 (6)
2 (2)
1 (1)

DISCUSSION
In this cohort of infants with severe BPD, over half the infants
receiving invasive mechanical ventilation were exposed to daily
diuretics, short-acting bronchodilators, and/or inhaled steroids.
These common drug exposures occur despite lack of FDA
labelling for these medications in this patient population. These
data conﬁrm that pediatric providers are using these drugs
commonly in real-world settings, and that there is an urgent
need for collaboration between providers and regulators to
complete the needed safety, efﬁcacy and pharmacokinetic studies
to conﬁrm that we are using the right doses in the right infants at the
right time.
A very interesting ﬁnding of this study is that, in almost all
cases, drug exposure is higher in those infants who remain
invasively ventilated. This could reﬂect a phenomenon in
which providers do not give drugs to infants who are more
“well” and use drugs more frequently in infants with more severe
lung disease. On the other hand, the high prevalence of these drug
exposures in the children with more severe lung disease, as
manifest by their invasive ventilation, may suggest that these
drugs are not efﬁcacious in modifying BPD severity or
progression, at least at the timing and doses most used. It is
also possible that this subset of infants who remain intubated at
and after 36 weeks would be even sicker without the use of these
drugs. Large, well designed randomized clinical trials are urgently
needed to understand the role of these drugs in sBPD.
Some of the most common drug exposures have been
associated with drug toxicities. 38% of the infants invasively
ventilated were on daily furosemide. This is very different than
the standard use of furosemide in the Neonatal ICU, which is a
median exposure of 2 days and cumulative exposure of less than
4 mg/kg (Thompson et al., 2020). Furosemide has been associated

<0.01
1.0
<0.01

Data are displayed as N (%).
Bold p-value indicates 2-tailed Fisher’s Exact test < 0.05.
a
No infants on the study were treated with beclomethasone.

Point prevalence of drug exposures were assessed by drug class
(i.e., Diuretics) and by individual drug exposures (i.e., furosemide).
Rates of drug exposure by drug class are presented in Table 2;
Figure 1. Diuretics were the drug class that most subjects were
receiving on the day of study (54%), followed by inhaled steroids
(47%) and short-acting bronchodilators (42%). Inhaled nitric
oxide (NO) was the drug that fewest subjects were on the day
of the study (6%), followed by anti-acids (14%), and long-acting
bronchodilators (15%). Seventeen percent of the entire cohort was
on no medications on the study day: 4% in the invasive mechanical
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Many of the children in this cohort were on systemic steroids,
48% in the invasively ventilated group and 18% in the noninvasive respiratory support group. The most used systemic
corticosteroids were hydrocortisone and prednisolone. The
ﬁnding of hydrocortisone use in this relatively older neonatal
population (older than 36 weeks PMA) is unexpected and may
reﬂect prolonged adrenal insufﬁciency after early-life systemic
steroid exposure. Unfortunately, we do not have the data to test
this postulate. The second most commonly used steroid,
prednisolone, has not been extensively studied in sBPD. In the
largest cohort published, 43 infants received prednisolone at an
average age of 42 weeks PMA and were treated for a median of
67 days (Linafelter et al., 2019). In this cohort, there was modest
short-term improvement in Pulmonary Severity Score at one
week with no beneﬁt beyond that, and linear growth was
impaired. In our study, 52% of infant receiving invasive
mechanical ventilation were on inhaled steroids. While there
are published studies on the utility of inhaled steroids to prevent
BPD (Shinwell et al., 2016), there is little research on the use of
inhaled steroids in infants with established BPD.
Drugs to block gastric acid production were also seen in the
invasively ventilated group, with one in ﬁve infants exposed. New
data highlights the long-term risks of early-life acid suppression
including increased risks of infection (Canani et al., 2006; Santos
et al., 2019) and later allergies (Trikha et al., 2013; Mitre et al.,
2018; Robinson and Camargo, 2018). Because of the common
belief that aspirated acid reﬂux can worsen BPD associated
pulmonary hypertension, we assessed the number of infants
treated simultaneously with anti-acid drugs and pulmonary
hypertension drugs. Eight of the 26 infants treated with antiacid drugs were on a pulmonary hypertension drug (systemic or
inhaled). Given limited data on the beneﬁt of these drugs in BPD,
we may be exposing infants to drugs with limited clinical beneﬁt
and signiﬁcant clinical harm.
In summary, all the drug use described in this study is
classiﬁed as “off-label” meaning there is no FDA labelling to
support safety nor efﬁcacy in infants with established BPD. The
authors posit that BPD is the quintessential example of a common
and severe disease for which no speciﬁc therapies have been
developed or proven, leaving clinicians to borrow drugs from
other patient populations and other diseases and use them to the
best of their knowledge. This is clearly unacceptable given the
risks of all the drug classes studied and underscores the need to
urgently prioritize and perform drug pharmacokinetic, safety,
and efﬁcacy trials with a goal of drug labelling in infants with
sBPD. When loss of equipoise has occurred, as manifest by
common off-label use, this task becomes more challenging.
The unique data captured by our study, clearly demonstrates
patterns of drug use in sBPD and can inform the design of future
studies to enrich for patient populations which are already being
clinically exposed to the drug of interest.

FIGURE 1 | Drug Class Exposure by Ventilation Status.

with secondary hyperparathyroidism in an infant with tracheostomy
and severe BPD (Srivastava et al., 2017). Chronic furosemide has
also been associated with hearing loss and nephrolithiasis. In a
study of a large cohort of preterm infants who received furosemide
for more than 28 consecutive days and who were propensity score
matched to a non-exposed group of infants (Wang et al., 2018),
prolonged furosemide exposure was associated with a trend toward
an increase in abnormal hearing screens (Wang et al., 2018). A
large systemic review published in 2018 showed no increased risk
of sensorineural hearing loss or nephrocalcinosis in preterm infants
exposed to furosemide but noted that the quality of evidence was
low (Jackson et al., 2018).
The exposure to inhaled medication in over 40% of our
cohorts is similar to that found in prior reports of medication
use in Neonatal ICU for BPD (Allen et al., 2003; Guaman et al.,
2015; Slaughter et al., 2015; Bamat et al., 2019). Most research has
involved preterm infants and those with evolving BPD (Wilkie
and Bryan, 1987; Rotschild et al., 1989; Pfenninger and Aebi,
1993; Lee et al., 1994; Sivakumar et al., 1999; Morrow et al., 2015;
Bassler et al., 2018), however little research has been performed to
determine safety and efﬁcacy for infants with sBPD. Napolitano
et al., investigated the safety and tolerability of two doses of
albuterol (1.25 and 2.5 mg) against placebo (3% saline) in infants
with sBPD requiring invasive mechanical ventilation (Napolitano
et al., 2021). Infants that responded to albuterol did with the
2.5 mg dose and showed a reduction in PIP while on volume
ventilation with no clinically meaningful change in heartrate.
There have been no trials on the utilization of inhaled steroids for
infants with established sBPD.
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